Regulatory Incentives and Knowledge Dynamics in Pharmaceutical Innovation: Evidence from Breakthrough Therapy Designation

Abstract

Pharmaceutical innovation heavily depends on scientific knowledge, but it is also shaped by regulatory institutions that define safety and efficacy requirements for market entry and influence time to market. This study examines whether the U.S. Food and Drug Administration’s Breakthrough Therapy Designation (BTD), introduced under the Food and Drug Administration Safety and Innovation Act (FDASIA) in 2012, is associated with changes in scientific publication activity. Using FDA approval records and publication data from the Web of Science Core Collection, the pilot analysis examines nine drugs across three disease areas: leukemia, lymphoma, and multiple myeloma. BTD-designated drugs were matched with non-BTD drugs based on comparable indications and approval timing within the 2013–2023 study window. Annual publication counts were measured over six-year periods before and after the designation and analyzed using an event-time difference-in-differences model with drug and relative-period fixed effects. Publication activity increased after designation, and the descriptive increase was larger for BTD-designated drugs than for non-BTD drugs. However, the fixed-effects estimate was positive but not statistically significant (β = 0.116, SE = 0.569). The findings suggest a possible increase in scientific publication activity following BTD designation, although the statistical evidence remains inconclusive. The findings suggest that regulatory incentives may influence clinical development without a comparable change in scientific knowledge production.